Immunomonitoring of Circulating Immune Cells in Maxillofacial Surgery

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

The immune response following facial reconstruction may help predict healing time and the date of discharge after maxillofacial surgery. Regulatory T cells (Tregs) are emerging as powerful modulators of the immune response in various contexts during reconstruction. Indeed, Tregs are involved in tissue regeneration, control the local inflammatory response, and promote effective tissue repair while limiting fibrosis. An early increase in circulating Tregs could serve as an indicator of a favorable reparative/regenerative response.

Primary objective: To identify changes in the proportion of regulatory T cells (Tregs) among circulating immune cells between the preoperative and postoperative periods, and to assess its association with length of hospital stay.

Primary outcome measure: proportion of regulatory T cells (Tregs) among CD4 lymphocytes, measured by flow cytometry at different time points (preoperative, perioperative, and postoperative), and its association with length of hospital stay (days).

Study Design: monocentric, including a maximum of 60 patients;

Inclusion criteria: Age ≥ 18 years; managed in the department of maxillofacial surgery (Pitié-Salpêtrière Hospital); Scheduled for surgery as part of treatment involving free flap reconstruction; Informed about the study, with no objections, and having provided written consent for genetic testing

Exclusion criteria: Pregnant or breastfeeding women; Individuals under legal protective measures

Research Process:

After verifying eligibility criteria, patients will be informed about the study during a clinical visit. Following a reflection period that the patient deems necessary to make a decision, their lack of objection and consent to genetic testing will be obtained. As part of the research, a 7 mL tube of ACD blood will be collected in addition to the routine blood samples during routine blood draws at the following visits: preoperative, perioperative (during surgery), and postoperative follow-ups (Day 2, Day 5, and Day 15). These tubes will then be analyzed in the Immunology Research Laboratory of Prof. Miyara and Dr. Bouaoud (CIMI, Pitié Salpêtrière) using flow cytometry (counting/assay of Tregs and subpopulations). During the operation, surgical waste (bone, muscle, drainage fluids) will also be collected for research purposes; it will be analyzed in the immunology research laboratory of Prof. Miyara and Dr. Bouaoud (CIMI, Pitié Salpêtrière) using flow cytometry and, in some cases, single-cell transcriptomics when the sample meets the necessary quality criteria (sufficient cell count, viability, etc.).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years

managed in the department of maxillofacial surgery (Pitié-Salpêtrière Hospital)

Scheduled for surgery as part of treatment involving free flap reconstruction

Informed about the study, with no objections, and having provided written consent for genetic testing

Disqualifiers

Pregnant or breastfeeding women

Individuals under legal protective measures

Trial population

Patients admitted to the Maxillofacial Surgery Department for a scheduled procedure involving free flap reconstruction.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Treg

    Other intervention

    A 7-mL tube of ACD blood will be collected in addition to the routine blood draw tubes during routine blood draws at the following visits: preoperative, perioperative (during surgery), and postoperative follow-ups (Day 2, Day 5, and Day 15). These tubes will then be analyzed in the Immunology Research Laboratory of Prof. Miyara and Dr. Bouaoud (CIMI, Pitié-Salpêtrière) using flow cytometry (counting and quantifying Tregs and subpopulations). Translated with DeepL.com (free version)

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Tregs proportion

Proportion of regulatory T cells (Tregs) among CD4 lymphocytes, measured by flow cytometry at different time points (preoperative, perioperative, and postoperative), and association with length of hospital stay (days).

Time frame
preoperative (Day -1), perioperative (Day 0), and postoperative (Day 2, Day 7, Day 15, Day of discharge)

Secondary outcomes

1

Tregs kinetics and surgical wound

Kinetics of the increase in circulating Tregs over the course of blood draws (preoperative visit, perioperative period, postoperative follow-up during hospitalization). Associated clinical criteria: time to healing/closure of the surgical wound

Time frame
preoperative (Day -1), perioperative (Day 0), and postoperative (Day 2, Day 7, Day 15, Day of discharge)
2

Tregs kinetics and patient discharge

Kinetics of the increase in circulating Tregs over the course of blood draws (preoperative visit, perioperative period, postoperative follow-up during hospitalization). Associated clinical criteria: time until the decision to discharge the patient from the hospital.

Time frame
preoperative (Day -1), perioperative (Day 0), and postoperative (Day 2, Day 7, Day 15, Day of discharge)

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: